Translating groundbreaking
scientific discoveries into major
therapeutic advances
A nonprofit drug discovery hub
An institute like no other: Accelerating new preventions, treatments and cures
The Calibr-Skaggs Institute for Innovative Medicines is a pioneering translational research institute dedicated to accelerating the next generation of medicines for critical unmet needs. We are a leading nonprofit drug discovery engine bringing treatments from discovery into the clinic across multiple disease areas.
As a division of Scripps Research—the largest private, nonprofit biomedical research organization in the United States ranked for its impact on innovation—we leverage a wide range of world-renowned, pioneering scientific approaches and technologies. Our self-sustaining model encourages bold exploration of ideas with far-reaching impact, while facilitating the transition of these ideas into clinical development.
Addressing unmet medical needs
Translating lab discoveries to the clinic: Bench to bedside
Calibr-Skaggs is dedicated to delivering groundbreaking solutions for unmet medical needs by uniting the creativity of fundamental discovery with the focus and R&D capabilities of industry. Our exceptional expertise and infrastructure enable us to seamlessly combine world-class research with our unique “bench to bedside” drug discovery engine. Our agile operations are designed to foster collaboration and expedite drug discovery programs into clinical development.
Lasting and impactful collaborations
Partnerships to impact disease
At Calibr-Skaggs, we believe that partnerships are the key to unlocking the potential of science for human health. We partner with leading companies, researchers, and nonprofits to develop and deliver novel therapies based on new biological and clinical insights.
We forge meaningful and productive collaborations throughout the life sciences ecosystem to discover and develop new therapies and accelerate their impact on conditions ranging from neglected and infectious diseases to cancer and chronic disease. These partnerships have allowed Calibr-Skaggs to create a self-sustaining, evergreen funding model, which reinvests revenues to further our mission.
Explore opportunities to join us in our quest to develop novel therapeutics targeting a broad spectrum of unmet medical needs.